Artificially synthesized mRNA and its uses
Artificially synthesized mRNA with complementary 5' and 3' UTRs from GAPDH enhances translation efficiency, addressing low efficiency and instability issues, enabling effective gene therapy.
Patent Information
- Application Number
- JP2021552479
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-17
- Filing Date
- 2020-10-16
- Publication Date
- 2024-11-11
- Estimated Expiration
- 2040-10-16
AI Technical Summary
Existing mRNA-based therapies face challenges with low translation efficiency and instability, which limits their effectiveness in gene therapy applications.
Artificially synthesized mRNA is designed with a 5' untranslated region (UTR) and a 3' UTR that have a complementarity of 40% to 80% with the 5' UTR, specifically using sequences from glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to enhance translation efficiency.
The designed mRNA exhibits significantly improved translation efficiency, leading to higher protein expression levels and stability, making it suitable for various therapeutic and genetic applications.
Smart Images

Figure 0007580125000001 
Figure 0007580125000002 
Figure 0007580125000003
Abstract
Description
[Technical field]
[0001] The present invention relates to an artificially synthesized mRNA and its use. This application claims priority based on Japanese Patent Application No. 2019-189929 filed on October 17, 2019, the entire contents of which are incorporated by reference. [Background technology]
[0002] Until now, gene therapy has been carried out using DNA, including viruses, as vectors, but the risk of cancer due to integration into the genome remains a major issue. On the other hand, mRNA has been attracting attention as a safe nucleic acid medicine that, unlike DNA, does not pose the risk of insertion into the genome, but the inherent instability and low translation efficiency of RNA have been pointed out as drawbacks (e.g., Patent Documents 1 to 3).
[0003] Patent Document 1 discloses a method of suppressing the occurrence of the intracellular degradation mechanism of mRNA by applying a functional inhibitor of 2'-5'-oligoadenylate synthetase to the mRNA of a target gene. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2018-74954 A [Patent Document 2] JP 2015-221026 A [Patent Document 3] JP 2015-226531 A Summary of the Invention [Problem to be solved by the invention]
[0005] It is true that the inherent instability of RNA can be improved by the technology described in Patent Document 1. However, there is still room for improvement in terms of improving the translation efficiency of mRNA.
[0006] Therefore, the present inventors have conducted extensive research and have come up with the invention of a method for improving the translation efficiency of mRNA. [Means for solving the problem]
[0007] The present invention has been made to solve the above-mentioned problems, and can be realized in the following forms.
[0008] (1) According to one embodiment of the present invention, there is provided an artificially synthesized mRNA, which comprises a 5' untranslated region of an mRNA encoding a protein and a 3' untranslated region having a complementarity of 40% to 80% with respect to the 5' untranslated region.
[0009] (2) In the above-mentioned artificially synthesized mRNA, the protein may be selected from the group consisting of glyceraldehyde-3-phosphate dehydrogenase, β-globin, RPS8, and LDHB.
[0010] (3) In the above-mentioned artificial synthetic mRNA, the 3' untranslated region may have a complementarity of 50% or more and 75% or less to the 5' untranslated region.
[0011] (4) According to another aspect of the present invention, there is provided a method comprising the step of introducing the above-mentioned artificial synthetic mRNA into a cell.
[0012] (5) According to another aspect of the present invention, there is provided a cell into which the above-mentioned artificial synthetic mRNA has been introduced.
[0013] (6) According to another aspect of the present invention, there is provided a method for producing an artificial synthetic mRNA, comprising the steps of preparing an artificial synthetic mRNA comprising a 5' untranslated region of an mRNA encoding a protein and a 3' untranslated region having a complementarity of 40% or more and 80% or less with the 5' untranslated region.
[0014] (7) According to another aspect of the present invention, there is provided an artificially synthesized mRNA, which comprises a 5' untranslated region of an mRNA encoding glyceraldehyde-3-phosphate dehydrogenase and a 3' untranslated region of an mRNA encoding glyceraldehyde-3-phosphate dehydrogenase.
[0015] (8) According to another aspect of the present invention, there is provided a method for producing an artificial synthetic mRNA, comprising the steps of preparing an artificial synthetic mRNA comprising a 5' untranslated region of an mRNA encoding glyceraldehyde-3-phosphate dehydrogenase and a 3' untranslated region of an mRNA encoding glyceraldehyde-3-phosphate dehydrogenase.
[0016] (9) According to another aspect of the present invention, there is provided a method comprising the step of introducing the artificial synthetic mRNA according to (7) above into a cell.
[0017] (10) According to another aspect of the present invention, there is provided a cell into which the artificial synthetic mRNA according to (7) above has been introduced. [Brief description of the drawings]
[0018] [Figure 1] A diagram showing the artificially synthesized mRNA produced. [Diagram 2] FIG. 1 shows the results of measuring the amount of protein expressed from artificially synthesized mRNA. [Diagram 3] FIG. 2 is a diagram showing the stability of the artificially synthesized mRNA shown in FIG. 1. [Figure 4] A diagram showing the artificially synthesized mRNA produced. [Diagram 5] FIG. 1 shows the expression level of each artificially synthesized mRNA. [Figure 6] FIG. 1 shows the expression level of each artificial synthetic mRNA when the artificial synthetic mRNA was introduced into kidney-derived HEK293 cells. [Figure 7] A diagram showing the artificially synthesized mRNA produced. [Figure 8] FIG. 1 is a diagram showing the difference in expression level due to the presence or absence of the UTR sequence of GAPDH. [Figure 9] FIG. 1 shows the difference in expression level due to the presence or absence of the LDHB UTR sequence. [Figure 10] FIG. 1 is a diagram showing the difference in expression level due to the presence or absence of the ACAT2 UTR sequence. [Figure 11] A diagram showing the artificially synthesized mRNA produced. [Figure 12] FIG. 1 shows the difference in expression level due to the presence or absence of deletion of the 5'UTR sequence of GAPDH. [Figure 13] A diagram showing the artificially synthesized mRNA produced. [Figure 14] FIG. 1 shows the difference in expression level due to the presence or absence of deletion of the 3'UTR sequence of GAPDH. [Figure 15] A diagram showing the artificially synthesized mRNA produced. [Figure 16] A diagram showing the difference in expression level due to the presence or absence of 5'UTR 28nt and 3'UTR 28nt. [Figure 17] A diagram showing the artificially synthesized mRNA produced. [Figure 18] FIG. 1 shows differences in expression levels due to complementation. [Figure 19] A diagram showing the artificially synthesized mRNA produced. [Figure 20] FIG. 1 shows differences in expression levels due to complementation. [Figure 21] A diagram showing the artificially synthesized mRNA produced. [Figure 22] FIG. 1 is a graph showing the difference in expression level when the tumor suppressor gene p53 is used. [Figure 23] FIG. 13 is a diagram for explaining a presumed mechanism of the obtained effect. [Figure 24] A diagram showing the difference in expression levels when the genome editing gene hCas9 is used. [Diagram 25]A diagram showing the difference in the amount of genome editing when using the genome editing gene hCas9. [Figure 26] A diagram showing the difference in expression level when the 5'UTR of β-globin is used. [Figure 27] A diagram showing the difference in expression level when the 5'UTR of RPS8 is used. [Figure 28] A diagram showing the difference in expression level when LDHB 5'UTR is used. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] The disclosure of this specification relates to an artificially synthesized mRNA with high translation efficiency and its use. The mRNA of the present invention may be referred to as "artificially synthesized mRNA" to indicate the characteristic that it is prepared by artificial manipulation and to distinguish it from intracellular (endogenous) mRNA. In this specification, "mRNA" refers to RNA having base sequence information and structure that can be translated into protein. In addition, the two terms "suppression" and "inhibition" have overlapping meanings and are often used interchangeably. Therefore, in this specification, the term "suppression" is used consistently unless a distinction is particularly necessary from the context. "High translation efficiency" means an increase in the amount of translation.
[0020] 1. mRNA The mRNA of the present invention comprises a coding region of a gene of interest (a region that codes for a protein that is an expression product of the gene of interest). A "gene of interest" is a gene that is expressed in a cell using the mRNA of the present invention. Various genes can be used as genes of interest. A cell into which a gene of interest is expressed by introducing the mRNA of the present invention is also referred to as a "target cell" in this specification. Examples of genes of interest include enzymes (e.g., nucleases (ZFN (Zinc Finger Nuclease) and TALEN (Transcription Activator-Like Effector)) and the like. Examples of target genes include genes for cytokines, hormones, neurotransmitters, etc., genes whose functional decline (e.g., due to mutation) or deficiency causes disease, genes that function normally but whose expression is desired to be enhanced, genes that are not inherently possessed by target cells and whose expression is beneficial for the survival and maintenance of target cells, genes that act on target cells and encode proteins that enhance the inherent functions of target cells or proteins that cause target cells to exert functions different from the inherent functions of target cells, and genes that encode proteins that do not act on target cells but are secreted from target cells and act on surrounding cells (e.g., proteins involved in intercellular networks). Genes that encode proteins that do not substantially act on target cells and surrounding cells can also be target genes. Examples of such genes include genes that encode proteins used in pharmaceuticals, etc. (e.g., human erythropoietin gene, human fibrinogen gene, human serum albumin gene, human lactoferrin gene, human α-glucosidase gene). By employing such genes, it is possible to produce recombinant proteins that can be used as pharmaceuticals, etc. in target cells.
[0021] The target cells are not particularly limited, and for example, various eukaryotic cells can be used as target cells. More specifically, as the target cells, for example, various cells of mammals (human, monkey, cow, horse, rabbit, mouse, rat, guinea pig, hamster, etc.), such as cardiac muscle cells, smooth muscle cells, adipocytes, fibroblasts, bone cells, chondrocytes, osteoclasts, parenchymal cells, epidermal keratinocytes, epithelial cells (skin epidermal cells, corneal epithelial cells, conjunctival epithelial cells, oral mucosal epithelium, hair follicle epithelial cells, oral mucosal epithelial cells, respiratory tract mucosal epithelial cells, intestinal mucosal epithelial cells, etc.), endothelial cells (corneal endothelial cells, vascular endothelial cells, etc.), nerve cells, glial cells, spleen cells, pancreatic β cells, mesangial cells, Langerhans cells, hepatic cells, precursor cells or stem cells thereof, or induced pluripotent stem cells (iPS cells), mesenchymal stem cells (MSCs), embryonic stem cells (ES cells), embryonic germ cells (EG cells), embryonic tumor cells (EC cells), etc. can be used. Furthermore, as target cells, for example, passaged cells, cells induced to differentiate into a specific cell lineage, established cell lines (e.g., HeLa cells, CHO cells, Vero cells, HEK293 cells, HepG2 cells, COS-7 cells, NIH3T3 cells, Sf9 cells), etc. can be used.
[0022] The mRNA of the present invention may be introduced into target cells separated from a living body (i.e., isolated target cells) or into target cells that constitute a living body. Therefore, the present invention can be carried out in any of in vitro, in vivo, and ex vivo environments. Here, "isolated" refers to a state in which the cells are removed from their original environment (e.g., a state in which the cells constitute a living body). Therefore, isolated target cells usually exist in a culture vessel or a storage vessel, and can be artificially manipulated in vitro. Specifically, cells separated from a living body and in a cultured state outside the body (including established cells) qualify as isolated target cells. As long as they are in an isolated state in the above sense, they are isolated cells even if they form a tissue.
[0023] The isolated target cells can be prepared from a living body (e.g., a patient). Alternatively, cells obtained from the RIKEN Bioresource Center, National Institute of Technology and Evaluation, ATCC (American Type Culture Collection), DSMZ (German Collection of Microorganisms and Cell Cultures), etc. may be used as isolated target cells.
[0024] The mRNA of the present invention comprises a 5' untranslated region (5'UTR: 5' untranslated region) and a 3' untranslated region (3'UTR: 3' untranslated region).
[0025] The mRNA of one embodiment of the present invention comprises a 5'UTR of an mRNA encoding a protein, and a 3'UTR having a complementarity of 40% to 80% with the 5'UTR. In other words, the mRNA of the embodiment of the present invention comprises a translation region encoding a target protein, a 5'UTR of an mRNA encoding a protein different from the target protein, and a 3'UTR having a complementarity of 40% to 80% with the 5'UTR. This configuration can improve the translation efficiency. From the viewpoint of further improving the translation efficiency, it is preferable that the complementarity of the 3'UTR with the 5'UTR is 50% to 75%. As a result of being able to improve the translation efficiency, the expression efficiency of the target protein can be improved.
[0026] The 5'UTR of an mRNA encoding a protein is not particularly limited. For example, the 5'UTR may be a 5'UTR that expresses a protein at a level of 10 6 The 5'UTR of an mRNA encoding a protein having one or more molecules is preferred, and more preferably, the protein is a protein selected from the group consisting of glyceraldehyde-3-phosphate dehydrogenase, β-globin, RPS8, and LDHB.
[0027] Furthermore, the mRNA of another embodiment of the present invention comprises a 5'UTR of an mRNA encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and a 3'UTR of an mRNA encoding GAPDH. In other words, the mRNA of the embodiment of the present invention comprises a 5'UTR of an mRNA encoding GAPDH, a 3'UTR of an mRNA encoding GAPDH, and an ORF (Open Reading Frame) encoding a protein other than GAPDH. This form can improve translation efficiency. In this specification, "UTR of an mRNA encoding ~" is also simply referred to as "UTR of ~". For example, "5'UTR of an mRNA encoding GAPDH" is also referred to as "UTR of GAPDH".
[0028] In the present specification, the UTR of GAPDH is a UTR of GAPDH derived from human, but the present invention is not limited thereto. For example, the UTR of GAPDH derived from other organisms (e.g., mouse) may be used as the UTR of GAPDH. The length of the UTR of GAPDH in the mRNA of the present invention is preferably 70% to 130%, more preferably 80% to 120%, and even more preferably 90% to 110% of the UTR of GAPDH derived from an organism. The UTR of GAPDH in the mRNA of the present invention has a degree of identity with the UTR of GAPDH derived from an organism of preferably 70% or more, more preferably 80% or more, and even more preferably 90% or more.
[0029] The mRNA of another embodiment of the present invention comprises a 5'UTR of an mRNA encoding GAPDH, and a 3'UTR having a complementarity of 40% to 80% with the 5'UTR. In other words, the mRNA of the embodiment of the present invention comprises a 5'UTR of an mRNA encoding GAPDH, a 3'UTR having a complementarity of 40% to 80% with the 5'UTR, and an ORF encoding a protein other than GAPDH. This form can improve the translation efficiency. From the viewpoint of further improving the translation efficiency, it is preferable that the complementarity of the 3'UTR with the 5'UTR is 50% to 75%.
[0030] The mRNA of this embodiment has a 5' cap structure (m 7 The mRNA may have a poly(A) chain and a 5' cap structure (a structure in which G (7-methylguanosine) is bound to the 5'-terminal nucleoside via a 5'-5' triphosphate bridge). The length of the poly(A) chain is not particularly limited, but is, for example, 30 to 200 bases. The translation initiation factor eIF4E binds to the 5' cap structure, and the poly(A) chain-binding protein PABP binds to the poly(A) chain, forming a complex via the translation initiation factor eIF4G, which is a scaffold protein, and the mRNA forms a circular structure (Wells SE, et al. Mol Cell. 1998;2:135-140). Furthermore, the translation termination factor eRF3 loops out the 3'UTR by forming a complex with PABP-eIF4G (Uchida N, et al. J Biol Chem. 2002;277:50286-50292). Such mRNA circularization brings the translation termination site and translation initiation site closer together physically, and recycles ribosomes that have completed translation from the termination codon to the next translation initiation without passing through the 3´UTR, thereby greatly contributing to the efficiency of translation initiation. The 5´ cap structure and poly(A) tail not only improve translation efficiency, but also stabilize mRNA by inhibiting mRNA degradation from the end by exonucleases, thus greatly contributing to post-transcriptional gene expression control in both the processes of translation efficiency and mRNA stabilization.
[0031] The mRNA of the present invention can be prepared, for example, by an in vitro transcription system, chemical synthesis, or other methods. By using an in vitro transcription kit (e.g., RiboMAX system provided by Promega, CUGA7 in vitro transcription kit provided by Nippon Gene, MEGAscript T7 kit provided by Life Technologies), it is possible to easily prepare the target mRNA. In addition, the addition of a 5' cap structure can be performed by a known method, for example, 3'-O-Me-m7G(5')ppp(5')G RNA Cap Structure Analog provided by New England Biolabs can be used.
[0032] As the mRNA of the present invention, two or more types of mRNA may be used in combination. For example, an mRNA having a coding region of a specific gene and an mRNA having a region encoding an expression product that interacts with the expression product of the gene may be used in combination.
[0033] The amount of the mRNA of the present invention may be set so that a sufficient amount of expression product is obtained in the target cells, taking into consideration the purpose of use, the characteristics of the target gene used, the type of target cells, etc. As an example of the amount of mRNA, 0.5 to 1.0 μg of mRNA may be contained per 3 cm culture dish as the amount for one use.
[0034] For the purpose of protecting the artificially synthesized mRNA, for example, exonuclease inhibitors, endonuclease inhibitors, phospholipids, calcium phosphate, polyethyleneimine, polyethylene glycol-polycations as nanomicelle forming agents, buffers, inorganic salts, divalent ions, etc. may be used, and for the purpose of preventing bacterial contamination, antibiotics, etc. may be used, and for the purpose of enhancing the proliferation ability of cells, animal serum, growth factors, sugars, vitamins, divalent ions, etc. may be used. In addition, other ingredients that are acceptable for formulation (for example, carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, antiseptics, physiological saline, etc.) may be used. Furthermore, for the purpose of enhancing the efficiency of cell introduction of active ingredients, special synthetic media such as Opti-MEM provided by Life Technologies may be used.
[0035] 2. Installation method In order to express a gene of interest in a target cell using the present invention, a step of introducing mRNA of the gene of interest into the target cell is carried out.
[0036] Introduction of mRNA into target cells can be carried out by known methods, such as calcium phosphate coprecipitation, electroporation (Potter, H. et al., Proc. Natl. Acad. Sci. USA 81, 7161-7165(1984)), lipofection (Felgner, PL et al., Proc. Natl. Acad. Sci. USA 84,7413-7417(1987)), microinjection (Graessmann, M. & Graessmann, A., Proc. Natl. Acad. Sci. USA 73,366-370(1976)), Hanahan's method (Hanahan, D., J. Mol. Biol. 166, 557-580(1983)), and lithium acetate method (Schiestl, RH et al., Curr. Genet. 16, 339-346(1989)), protoplast-polyethylene glycol method (Yelton, MM et al., Proc. Natl. Acad. Sci. 81, 1470-1474(1984)), ultrasonic gene transfer method, a method using cationic polyamine acid (see, for example, JP 2011-173802 A), a method using a polyion complex (PIC) type polymer micelle consisting of a block copolymer having a cationic polymer segment and a non-crosslinked hydrophilic polymer segment (see, for example, JP 2004-352972 A and WO 2012 / 005376 A pamphlet), and the like.
[0037] 3.Applications According to the mRNA of the present invention, translation efficiency is improved in target cells, resulting in high expression of a target protein. Therefore, the present invention can be applied to various uses in which high expression of a target protein is desired. Examples of uses of the present invention include (A) treatment of various viral diseases (e.g., hepatitis B, acquired immune deficiency syndrome (AIDS), adult T-cell leukemia) and genetic diseases (e.g., Duchenne muscular dystrophy, cystic fibrosis, β-thalassemia, Hurler syndrome, retinitis pigmentosa, X-linked nephrogenic diabetes insipidus), (B) cancer immunotherapy, (C) production of iPS cells, and (D) differentiation induction of stem cells (e.g., pluripotent stem cells such as iPS cells and ES cells) or progenitor cells.
[0038] The above (A) and (B) are applications of the present invention as a so-called RNA medicine. In the treatment of hepatitis B as a specific example of (A), for example, by using an mRNA incorporating a nuclease (ZFN, TALEN, or CRISPR-Cas9) gene that cleaves and degrades viral DNA incorporated into the genome as a target gene, viral treatment without the risk of carcinogenesis, which is a problem in conventional methods using viral vectors, is possible. Thus, the present invention is also useful as a virus removal agent. In the treatment of genetic diseases, for example, a disease-causing gene (one that causes a disease due to functional impairment or deficiency) is used as a target gene, and the present invention is applied. In the above use (B), the present invention is used to introduce mRNA of a cancer antigen into antigen-presenting cells, and a cancer vaccine is produced in the body. If the present invention is applied to the above uses (C) and (D), it becomes possible to introduce reprogramming factors without using a viral vector, thereby overcoming the problem of cell canceration.
[0039] When the present invention is used as an RNA drug, formulation can be carried out according to a conventional method. When the formulation is carried out, other components acceptable for formulation (e.g., buffers, excipients, disintegrants, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, antiseptics, physiological saline, carriers, etc.) can be contained. As the buffer, phosphate buffer, citrate buffer, etc. can be used. As the excipient, lactose, starch, sorbitol, D-mannitol, sucrose, etc. can be used. As the disintegrant, starch, carboxymethylcellulose, calcium carbonate, etc. can be used. As the buffer, phosphate, citrate, acetate, etc. can be used. As the emulsifier, gum arabic, sodium alginate, tragacanth, etc. can be used. As the suspending agent, glycerin monostearate, aluminum monostearate, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, sodium lauryl sulfate, etc. can be used. As the soothing agent, benzyl alcohol, chlorobutanol, sorbitol, etc. can be used. As the stabilizer, propylene glycol, ascorbic acid, etc. can be used. Examples of the preservative that can be used include phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, methylparaben, etc. Examples of the antiseptic that can be used include benzalkonium chloride, paraoxybenzoic acid, chlorobutanol, etc.
[0040] The dosage form of the formulation is not particularly limited, and examples of the dosage form include injections, tablets, powders, fine granules, granules, capsules, and syrups.
[0041] The RNA medicine of the present invention is administered to a subject by oral or parenteral administration (intravenous, intraarterial, subcutaneous, intradermal, intramuscular or intraperitoneal injection, transdermal, nasal, transmucosal, etc.) depending on its dosage form. These administration routes are not mutually exclusive, and any two or more selected may be used in combination (for example, intravenous injection at the same time as oral administration or after a certain time has passed). The "subject" here is not particularly limited, and includes humans and non-human mammals (including pet animals, livestock, and experimental animals. Specific examples include mice, rats, guinea pigs, hamsters, monkeys, cows, pigs, goats, sheep, dogs, cats, chickens, quails, etc.). In a preferred embodiment, the RNA medicine of the present invention is administered to humans.
[0042] The dosage of the RNA drug of the present invention is set so as to obtain the expected therapeutic effect. In setting a therapeutically effective dosage, the symptoms, age, sex, and body weight of the patient are generally taken into consideration. Those skilled in the art can set an appropriate dosage taking these factors into consideration. As an administration schedule, for example, once to several times a day, once every two days, or once every three days can be adopted. In creating an administration schedule, the symptoms of the patient and the duration of effect of the active ingredient can be taken into consideration. EXAMPLES
[0043] 1. Purpose Aiming to improve the translation efficiency in target cells of artificially synthesized mRNA, which is expected to have various clinical applications, we carried out the following studies.
[0044] 2. Research Materials and Methods (1) Plasmid pBK-5F-EGFP-pA72 was used as a vector for RNA transfection. pBK-5F-EGFP-pA72 was prepared according to the method described in Nogimori et al., “Dom34 mediates targeting of exogenous RNA in the antiviral OAS / RNase L pathway” Nucleic Acids Research, Volume 47, Issue 1, 10 January 2019, Pages 432-449.
[0045] (2) Insertion of a non-translated region Insertion of the 5´UTR of GAPDH As for the 5'UTR sequence of GAPDH, the oligonucleotides shown in SEQ ID NO: 1 and SEQ ID NO: 2 were hybridized and inserted into the KpnI and XhoI sites of pBK-5F-EGFP-pA72. Here, the 5'UTR sequence of GAPDH is shown in SEQ ID NO: 27.
[0046] Insertion of 3´UTR of GAPDH The 3'UTR sequence of GAPDH was isolated by reverse transcription PCR using total RNA extracted from HeLa cells and the oligonucleotides shown in SEQ ID NO: 3 and SEQ ID NO: 4. The isolated sequence was inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence of GAPDH is shown in SEQ ID NO: 28.
[0047] Insertion of 5´UTR of ACAT2 The 5'UTR sequence of ACAT2 was isolated by reverse transcription PCR using total RNA extracted from HeLa cells and the oligonucleotides shown in SEQ ID NO: 5 and SEQ ID NO: 6. The isolated sequence was inserted into the KpnI and XhoI sites of pBK-5F-EGFP-pA72. The 5'UTR sequence of ACAT2 is shown in SEQ ID NO: 29.
[0048] Insertion of the 3´UTR of ACAT2 The 3'UTR sequence of ACAT2 was isolated by reverse transcription PCR using total RNA extracted from HeLa cells and the oligonucleotides shown in SEQ ID NO: 7 and SEQ ID NO: 8. The isolated sequence was inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence of ACAT2 is shown in SEQ ID NO: 30.
[0049] Insertion of 5´UTR of LDHB The 5'UTR sequence of LDHB was isolated by reverse transcription PCR using total RNA extracted from HeLa cells and the oligonucleotides shown in SEQ ID NO: 9 and SEQ ID NO: 10. The isolated sequence was inserted into the KpnI and XhoI sites of pBK-5F-EGFP-pA72. The 5'UTR sequence of LDHB is shown in SEQ ID NO: 31.
[0050] Insertion of 3´UTR of LDHB The 3'UTR sequence of LDHB was isolated by reverse transcription PCR using total RNA extracted from HeLa cells and the oligonucleotides shown in SEQ ID NO: 11 and SEQ ID NO: 12. The isolated sequence was inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence of LDHB is shown in SEQ ID NO: 32.
[0051] Insertion of a 3´UTR that is completely complementary to the 5´UTR sequence of GAPDH As for the 3'UTR sequence that is completely complementary to the 5'UTR sequence of GAPDH, the oligonucleotides shown in SEQ ID NO: 13 and SEQ ID NO: 14 were hybridized and inserted into the KpnI and XhoI sites of pBK-5F-EGFP-pA72. Here, the 3'UTR sequence that is completely complementary to the 5'UTR sequence of GAPDH is shown in SEQ ID NO: 33.
[0052] Insertion of a 3´UTR with 94% complementarity to the 5´UTR sequence of GAPDH As for the 3'UTR sequence having 94% complementarity with the 5'UTR sequence of GAPDH, the oligonucleotides shown in SEQ ID NO: 15 and SEQ ID NO: 16 were hybridized and inserted into the KpnI and XhoI sites of pBK-5F-EGFP-pA72. Here, the 3'UTR sequence having 94% complementarity with the 5'UTR sequence of GAPDH is shown in SEQ ID NO: 34.
[0053] Insertion of a 3´UTR with 88% complementarity to the 5´UTR sequence of GAPDH As for the 3'UTR sequence having 88% complementarity with the 5'UTR sequence of GAPDH, the oligonucleotides shown in SEQ ID NO: 17 and SEQ ID NO: 18 were hybridized and inserted into the KpnI and XhoI sites of pBK-5F-EGFP-pA72. Here, the 3'UTR sequence having 88% complementarity with the 5'UTR sequence of GAPDH is shown in SEQ ID NO: 35.
[0054] Insertion of a 3´UTR with 75% complementarity to the 5´UTR sequence of GAPDH As for the 3'UTR sequence having 75% complementarity with the 5'UTR sequence of GAPDH, the oligonucleotides shown in SEQ ID NO: 19 and SEQ ID NO: 20 were hybridized and inserted into the KpnI and XhoI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence having 75% complementarity with the 5'UTR sequence of GAPDH is shown in SEQ ID NO: 36.
[0055] Insertion of a 3´UTR with 50% complementarity to the 5´UTR sequence of GAPDH As for the 3'UTR sequence having 50% complementarity with the 5'UTR sequence of GAPDH, the oligonucleotides shown in SEQ ID NO: 21 and SEQ ID NO: 22 were hybridized and inserted into the KpnI and XhoI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence having 50% complementarity with the 5'UTR sequence of GAPDH is shown in SEQ ID NO: 37.
[0056] Insertion of a 3´UTR with 25% complementarity to the 5´UTR sequence of GAPDH As for the 3'UTR sequence having 25% complementarity with the 5'UTR sequence of GAPDH, the oligonucleotides shown in SEQ ID NO: 23 and SEQ ID NO: 24 were hybridized and inserted into the KpnI and XhoI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence having 25% complementarity with the 5'UTR sequence of GAPDH is shown in SEQ ID NO: 38.
[0057] Insertion of β-globin 5´UTR For the 5'UTR sequence of β-globin, the oligonucleotides shown in SEQ ID NO: 41 and SEQ ID NO: 42 were hybridized and inserted into the KpnI and XhoI sites of pBK-5F-EGFP-pA72. The 5'UTR sequence of β-globin is shown in SEQ ID NO: 94.
[0058] Insertion of a 3´UTR that is completely complementary to the 5´UTR sequence of β-globin As for the 3'UTR, which is completely complementary to the 5'UTR sequence of β-globin, the oligonucleotides shown in SEQ ID NO: 43 and SEQ ID NO: 44 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. Here, the 3'UTR sequence, which is completely complementary to the 5'UTR sequence of β-globin, is shown in SEQ ID NO: 95.
[0059] Insertion of a 3´UTR with 92% complementarity to the 5´UTR sequence of β-globin For the 3'UTR, which has 92% complementarity with the 5'UTR sequence of β-globin, the oligonucleotides shown in SEQ ID NO: 45 and SEQ ID NO: 46 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which has 92% complementarity with the 5'UTR sequence of β-globin, is shown in SEQ ID NO: 96.
[0060] Insertion of a 3´UTR with 88% complementarity to the 5´UTR sequence of β-globin For the 3'UTR, which has 88% complementarity with the 5'UTR sequence of β-globin, the oligonucleotides shown in SEQ ID NO: 47 and SEQ ID NO: 48 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which has 88% complementarity with the 5'UTR sequence of β-globin, is shown in SEQ ID NO: 97.
[0061] Insertion of a 3´UTR with 74% complementarity to the 5´UTR sequence of β-globin As for the 3'UTR, which has 74% complementarity with the 5'UTR sequence of β-globin, the oligonucleotides shown in SEQ ID NO: 49 and SEQ ID NO: 50 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which has 74% complementarity with the 5'UTR sequence of β-globin, is shown in SEQ ID NO: 98.
[0062] Insertion of a 3´UTR with 50% complementarity to the 5´UTR sequence of β-globin As for the 3'UTR having 50% complementarity with the 5'UTR sequence of β-globin, the oligonucleotides shown in SEQ ID NO:51 and SEQ ID NO:52 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence having 50% complementarity with the 5'UTR sequence of β-globin is shown in SEQ ID NO:99.
[0063] Insertion of a 3´UTR with 24% complementarity to the 5´UTR sequence of β-globin As for the 3'UTR, which has 24% complementarity with the 5'UTR sequence of β-globin, the oligonucleotides shown in SEQ ID NO: 53 and SEQ ID NO: 54 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which has 24% complementarity with the 5'UTR sequence of β-globin, is shown in SEQ ID NO: 100.
[0064] Insertion of the 5´UTR of RPS8 For the 5'UTR sequence of RPS8, the oligonucleotides shown in SEQ ID NO:55 and SEQ ID NO:56 were hybridized and inserted into the KpnI and XhoI sites of pBK-5F-EGFP-pA72. Here, the 5'UTR sequence of RPS8 is shown in SEQ ID NO:101.
[0065] Insertion of a 3´UTR that is completely complementary to the 5´UTR sequence of RPS8 For the 3'UTR, which is completely complementary to the 5'UTR sequence of RPS8, the oligonucleotides shown in SEQ ID NO:57 and SEQ ID NO:58 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which is completely complementary to the 5'UTR sequence of RPS8, is shown in SEQ ID NO:102.
[0066] Insertion of a 3´UTR with 93% complementarity to the 5´UTR sequence of RPS8 For the 3'UTR, which is 93% complementary to the 5'UTR sequence of RPS8, the oligonucleotides shown in SEQ ID NO:59 and SEQ ID NO:60 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which is 93% complementary to the 5'UTR sequence of RPS8, is shown in SEQ ID NO:103.
[0067] Insertion of a 3´UTR with 86% complementarity to the 5´UTR sequence of RPS8 For the 3'UTR, which is 86% complementary to the 5'UTR sequence of RPS8, the oligonucleotides shown in SEQ ID NO:61 and SEQ ID NO:62 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which is 86% complementary to the 5'UTR sequence of RPS8, is shown in SEQ ID NO:104.
[0068] Insertion of a 3´UTR with 71% complementarity to the 5´UTR sequence of RPS8 For the 3'UTR, which has 71% complementarity with the 5'UTR sequence of RPS8, the oligonucleotides shown in SEQ ID NO:63 and SEQ ID NO:64 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which has 71% complementarity with the 5'UTR sequence of RPS8, is shown in SEQ ID NO:105.
[0069] Insertion of a 3´UTR with 50% complementarity to the 5´UTR sequence of RPS8 For the 3'UTR having 50% complementarity with the 5'UTR sequence of RPS8, the oligonucleotides shown in SEQ ID NO:65 and SEQ ID NO:66 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence having 50% complementarity with the 5'UTR sequence of RPS8 is shown in SEQ ID NO:106.
[0070] Insertion of a 3´UTR with 29% complementarity to the 5´UTR sequence of RPS8 For the 3'UTR, which has 29% complementarity with the 5'UTR sequence of RPS8, the oligonucleotides shown in SEQ ID NO:67 and SEQ ID NO:68 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which has 29% complementarity with the 5'UTR sequence of RPS8, is shown in SEQ ID NO:107.
[0071] Insertion of a 3´UTR with 14% complementarity to the 5´UTR sequence of RPS8 For the 3'UTR, which has 14% complementarity with the 5'UTR sequence of RPS8, the oligonucleotides shown in SEQ ID NO:69 and SEQ ID NO:70 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which has 14% complementarity with the 5'UTR sequence of RPS8, is shown in SEQ ID NO:108.
[0072] Insertion of a 3´UTR that is completely complementary to the 5´UTR sequence of LDHB For the 3'UTR, which is completely complementary to the LDHB 5'UTR sequence, the oligonucleotides shown in SEQ ID NO: 71 and SEQ ID NO: 72 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which is completely complementary to the LDHB 5'UTR sequence, is shown in SEQ ID NO: 109.
[0073] Insertion of a 3´UTR with 93% complementarity to the 5´UTR sequence of LDHB For the 3'UTR, which is 93% complementary to the LDHB 5'UTR sequence, the oligonucleotides shown in SEQ ID NO: 73 and SEQ ID NO: 74 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which is 93% complementary to the LDHB 5'UTR sequence, is shown in SEQ ID NO: 110.
[0074] Insertion of a 3´UTR with 87% complementarity to the 5´UTR sequence of LDHB For the 3'UTR, which is 87% complementary to the LDHB 5'UTR sequence, the oligonucleotides shown in SEQ ID NO: 75 and SEQ ID NO: 76 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence, which is 87% complementary to the LDHB 5'UTR sequence, is shown in SEQ ID NO: 111.
[0075] Insertion of a 3´UTR with 75% complementarity to the 5´UTR sequence of LDHB For the 3'UTR having 75% complementarity with the LDHB 5'UTR sequence, the oligonucleotides shown in SEQ ID NO: 77 and SEQ ID NO: 78 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence having 75% complementarity with the LDHB 5'UTR sequence is shown in SEQ ID NO: 112.
[0076] Insertion of a 3´UTR with 50% complementarity to the 5´UTR sequence of LDHB As for the 3'UTR having 50% complementarity with the LDHB 5'UTR sequence, the oligonucleotides shown in SEQ ID NO: 79 and SEQ ID NO: 80 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence having 50% complementarity with the LDHB 5'UTR sequence is shown in SEQ ID NO: 113.
[0077] Insertion of a 3´UTR with 25% complementarity to the 5´UTR sequence of LDHB For the 3'UTR having 25% complementarity with the LDHB 5'UTR sequence, the oligonucleotides shown in SEQ ID NO: 81 and SEQ ID NO: 82 were hybridized and inserted into the EcoRI and XbaI sites of pBK-5F-EGFP-pA72. The 3'UTR sequence having 25% complementarity with the LDHB 5'UTR sequence is shown in SEQ ID NO: 114.
[0078] Preparation of Cas9 mRNA synthesis plasmid The cDNA sequence of Cas9 was isolated by PCR using the hCas9 plasmid (Addgene plasmid # 41815) described in Mail et al. "RNA-guided human genome engineering via Cas9" Science. 2013 Feb 15;339(6121):823-6 and the oligonucleotides shown in SEQ ID NO: 83 and SEQ ID NO: 84. The isolated sequence was inserted into the HindIII site of pBK-5F-EGFP-pA72, and the pBK-F-hCas9-pA72 plasmid was obtained by inverse PCR using the oligonucleotides shown in SEQ ID NO: 83 and SEQ ID NO: 85. Here, the cDNA sequence of hCas9 is shown in SEQ ID NO: 115, and the amino acid sequence of hCas9 is shown in SEQ ID NO: 116.
[0079] Insertion of the 5´UTR of GAPDH into the Cas9 mRNA synthesis plasmid The 5'UTR of GAPDH was inserted by inverse PCR using the pBK-F-hCas9-pA72 plasmid and the oligonucleotides shown in SEQ ID NO: 86 and SEQ ID NO: 87. Here, the 5'UTR of GAPDH is shown in SEQ ID NO: 27.
[0080] Insertion of the 3´UTR, which has 75% complementarity with the 5´UTR sequence of GAPDH, into the Cas9 mRNA synthesis plasmid A 3'UTR having 75% complementarity to the 5'UTR sequence of GAPDH was inserted by inverse PCR using the pBK-F-hCas9-pA72 plasmid and the oligonucleotides shown in SEQ ID NO: 88 and SEQ ID NO: 89. The 3'UTR sequence having 75% complementarity to the 5'UTR sequence of GAPDH is shown in SEQ ID NO: 36.
[0081] Insertion of the 3´UTR with 50% complementarity to the 5´UTR sequence of GAPDH into the Cas9 mRNA synthesis plasmid A 3'UTR having 50% complementarity to the 5'UTR sequence of GAPDH was inserted by inverse PCR using the pBK-F-hCas9-pA72 plasmid and the oligonucleotides shown in SEQ ID NO: 90 and SEQ ID NO: 91. The 3'UTR sequence having 50% complementarity to the 5'UTR sequence of GAPDH is shown in SEQ ID NO: 37.
[0082] Insertion of p53 cDNA The cDNA sequence of p53 was isolated by reverse transcription PCR using total RNA extracted from U20S cells and the oligonucleotides shown in SEQ ID NO: 25 and SEQ ID NO: 26. The isolated cDNA sequence of p53 was inserted into the HindIII site of pBK-5F-EGFP-pA72. Here, the cDNA sequence of p53 is shown in SEQ ID NO: 39, and the amino acid sequence of p53 is shown in SEQ ID NO: 40.
[0083] (3)RNA synthesis Various pBK-5F-EGFP-pA72, various pBK-5F-p53-pA72 and various pBK-F-hCas9-pA72 plasmids were treated with BsmBI and used as templates to synthesize 5xFlag-EGFP-pA72, 5xFlag-p53-pA72 and Flag-hCas9-pA72 mRNA. RNA synthesis was performed using T7 RNA polymerase (Takara Bio Inc.) according to the instruction manual for this T7 RNA polymerase.
[0084] (4) Transfection HeLa cells, 293T cells, and U2OS cells were all cultured at 37°C in the presence of 5% CO2 in Dulbecco's Modified Eagle's Medium (Nissui Pharmaceutical Co., Ltd.) supplemented with 5% fetal bovine serum. HeLa cells were seeded on a 35 mm dish to be approximately 50% confluent and then cultured for 24 hours. After that, various synthesized RNAs were introduced using Lipofectamine RNAiMAX (Life Technologies Japan, Inc.) according to the instruction manual.
[0085] (5) RNA analysis Total RNA was isolated from HeLa cells after RNA transfection by the acid guanidinium thiocyanate-phenol-chloroform extraction (AGPC) method, which uses guanidine thiocyanate, acid phenol, and chloroform. The total RNA was separated on an agarose MOPS buffer gel (20 mM MOPS (pH 7.0), 5 mM sodium acetate, 1 mM EDTA, 2.0% agarose, 2.46 M formaldehyde) and then transferred to a nylon membrane Biodyne-B (Nihon Pall Co., Ltd.) in 20xSSC buffer. After transfer, the nylon membrane was fixed with UV and hybridized with a DIG-labeled probe. The preparation of the DIG-labeled probe and hybridization were performed using DIG RNA Labeling Mix (Roche Diagnostics KK) and DIG Wash and Block Buffer Set (Roche Diagnostics KK) according to the instruction manual. The mRNA was detected using the chemiluminescent reagent CDP-Star (Roche Diagnostics) with an LAS3000mini (Fuji Photo Film Co., Ltd.).
[0086] (6) Protein analysis Intracellular expression of proteins was performed by Western blotting as described below. Protein lysates from transfected cells were prepared using SDS-PAGE sample buffer (50 mM Tris-HCl (pH 6.8), 4% glycerol, 2% SDS, 2% 2-mercaptoethanol, 0.004% bromophenol blue). Protein lysates were separated by SDS-PAGE using 8, 10, 12, or 15% acrylamide, and then electrically transferred to a nitrocellulose membrane BioTrace NC (Nihon Pall Corporation). After transfer, the nitrocellulose membrane was incubated with anti-Flag M2 mouse monoclonal antibody (Sigma-Aldrich Japan, LLC), anti-GAPDH antibody (Saito et al. JBC), anti-PABPC1 antibody (Osawa et al. RNA (2012)), and peroxidase-conjugated anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc.) or peroxidase-conjugated anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc.). Peroxidase enzyme activity on the nitrocellulose membrane was detected using the luminol chemiluminescence method with an LAS3000mini (Fuji Photo Film Co., Ltd.).
[0087] (7) Quantification of AAVS genome editing efficiency Genome editing efficiency was quantified by the T7 endonuclease assay method shown below. Various hCas9 mRNAs synthesized with sgRNA (Thermo Fisher Scientific Co., Ltd.) that recognizes the AAVS region were introduced into HeLa cells. The introduced cells were treated with 50 mM NaOH to prepare genomic DNA. The AAVS genomic sequence was amplified by PCR using the prepared genomic DNA and the oligonucleotides shown in SEQ ID NO: 92 and SEQ ID NO: 93. The amplified genomic sequence was annealed after thermal denaturation to obtain a sequence containing mismatches. The annealed AAVS genomic sequence was treated with T7 endonuclease I (New England Biolabs, Inc.). The treated AAVS genomic sequence was separated by agarose gel electrophoresis, stained with ethidium bromide, and detected by Typhoon9400 (GE Healthcare Co., Ltd.).
[0088] 3. Experimental Results (i) Experiment 1 FIG. 1 is a diagram showing the prepared artificially synthesized mRNA. The artificially synthesized mRNAs shown in FIG. 1 are, from the top, an artificially synthesized mRNA having a 5'UTR sequence of GAPDH and a 3'UTR sequence of GAPDH, an artificially synthesized mRNA having a 5'UTR sequence of LDHB and a 3'UTR sequence of LDHB, and an artificially synthesized mRNA having a 5'UTR sequence of ACAT2 and a 3'UTR sequence of ACAT2. A cap structure was added to the 5' end of the artificially synthesized mRNA used in this experiment, and a 72-base polyA chain was added to the 3' end. In addition, the ORF, which is the protein coding region of the artificially synthesized mRNA used in this experiment, has EGFP (enhanced green fluorescent protein) with a 5xFlag tag added.
[0089] Figure 2 shows the results of measuring the amount of protein expressed from artificially synthesized mRNA. The amount of protein expressed was measured by introducing the artificially synthesized mRNA shown in Figure 1 into HeLa cells. Figure 2 shows the amount of expression for each artificially synthesized mRNA.
[0090] Fig. 2 shows the relative expression levels when the expression level of an artificially synthesized mRNA having the UTR sequence of ACAT2 is set to 1. For reference, Fig. 2 also shows the results for an artificially synthesized mRNA having the 3'UTR of β-globin.
[0091] From the results in Figure 2, it was found that the artificially synthesized mRNA having the UTR sequence of GAPDH showed about 10 times the expression level compared to the artificially synthesized mRNA having the UTR sequence of ACAT2. In addition, it was found that the artificially synthesized mRNA having the UTR sequence of GAPDH showed about 5 times the expression level compared to the artificially synthesized mRNA having the 3'UTR sequence of β-globin, which is a standard artificially synthesized mRNA with high expression efficiency.
[0092] Figure 3 is a diagram showing the stability of the artificial synthetic mRNA shown in Figure 1. The horizontal axis of Figure 3 shows the time elapsed since the artificial synthetic mRNA was introduced into the cells, and the vertical axis of Figure 3 shows the amount of mRNA when the amount of mRNA when the artificial synthetic mRNA was introduced into the cells is taken as 100%.
[0093] The results in Figure 3 show that all the artificially synthesized mRNAs show similar decomposition rates in HeLa cells. The results in Figures 2 and 3 show that the effect of the GAPDH 5'UTR sequence and the GAPDH 3'UTR sequence is not to improve stability but to improve translation efficiency.
[0094] (ii) Experiment 2 FIG. 4 is a diagram showing the prepared artificial synthetic mRNA. The artificial synthetic mRNAs shown in FIG. 4 are, from the top to the bottom, an artificial synthetic mRNA having the 5'UTR sequence of ACAT2 and the 3'UTR sequence of ACAT2, an artificial synthetic mRNA having the 5'UTR sequence of ACAT2 and the 3'UTR sequence of GAPDH, an artificial synthetic mRNA having the 5'UTR sequence of GAPDH and the 3'UTR sequence of ACAT2, and an artificial synthetic mRNA having the 5'UTR sequence of GAPDH and the 3'UTR sequence of GAPDH. A cap structure was added to the 5' end of the artificial synthetic mRNA used in this experiment, and a 72-base polyA chain was added to the 3' end. In addition, the ORF, which is the protein coding region of the artificial synthetic mRNA used in this experiment, has EGFP with a 5xFlag tag added.
[0095] Fig. 5 is a diagram showing the expression level for each artificially synthesized mRNA. The protein expression level was measured by introducing the artificially synthesized mRNA shown in Fig. 4 into HeLa cells. Fig. 5 shows the relative expression level when the expression level of the artificially synthesized mRNA having the 5'UTR sequence of ACAT2 and the 3'UTR sequence of ACAT2 is set to 1.
[0096] From the results of FIG. 5, it was found that the artificial synthetic mRNA having the 5'UTR sequence of GAPDH and the 3'UTR sequence of ACAT2 showed about 10 times the expression level compared to the artificial synthetic mRNA having the 5'UTR sequence of ACAT2 and the 3'UTR sequence of ACAT2. Furthermore, it was found that the artificial synthetic mRNA having the 5'UTR sequence of GAPDH and the 3'UTR sequence of GAPDH showed about 25 times the expression level compared to the artificial synthetic mRNA having the 5'UTR sequence of ACAT2 and the 3'UTR sequence of ACAT2. In other words, it was found that the translation efficiency was improved by having the 5'UTR sequence of GAPDH, and further, a synergistic translation efficiency improvement effect was obtained by having the 3'UTR sequence of GAPDH.
[0097] FIG. 6 is a diagram showing the expression level of each artificially synthesized mRNA when the artificially synthesized mRNA was introduced into kidney-derived HEK293 cells. Compared with the experiment related to FIG. 5, the experiment was performed in the same manner except that the cells to be introduced were changed. The results of FIG. 6 also showed the same tendency as that found from the results of FIG. 5. In other words, it was found that the effect of improving translation efficiency can be obtained by having the 5'UTR sequence of GAPDH, and further, a synergistic effect of improving translation efficiency can be obtained by having the 3'UTR sequence of GAPDH. From the experimental results related to FIG. 5 and FIG. 6, it was found that the effect of improving translation efficiency obtained by having the UTR sequence of GAPDH is effective in all cells and has no cell specificity.
[0098] (iii) Experiment 3 FIG. 7 is a diagram showing the prepared artificial synthetic mRNA. The artificial synthetic mRNAs shown in FIG. 7 are, from the top to bottom, an artificial synthetic mRNA without a UTR sequence, an artificial synthetic mRNA with a 5'UTR sequence but without a 3'UTR sequence, an artificial synthetic mRNA without a 5'UTR sequence but with a 3'UTR sequence, and an artificial synthetic mRNA with a 5'UTR sequence and a 3'UTR sequence. A cap structure was added to the 5' end of the artificial synthetic mRNA used in this experiment, and a 72-base polyA chain was added to the 3' end. In addition, the ORF, which is the protein coding region of the artificial synthetic mRNA used in this experiment, has EGFP with a 5xFlag tag added.
[0099] FIG. 8 is a diagram showing the difference in expression level caused by the presence or absence of a UTR sequence of GAPDH. FIG. 9 is a diagram showing the difference in expression level caused by the presence or absence of a UTR sequence of LDHB. FIG. 10 is a diagram showing the difference in expression level caused by the presence or absence of a UTR sequence of ACAT2. Protein expression levels were measured by introducing the artificially synthesized mRNA shown in FIG. 7 into HeLa cells. In FIGS. 8, 9, and 10, the relative values of expression levels are shown when the expression level of an artificially synthesized mRNA without a UTR sequence is set to 1.
[0100] From the results of Figure 8, the expression amount of the artificial synthetic mRNA having the 5'UTR sequence of GAPDH and the 3'UTR sequence of GAPDH is greater than the sum of the expression amount of the artificial synthetic mRNA having the 5'UTR sequence but not the 3'UTR sequence and the expression amount of the artificial synthetic mRNA having the 3'UTR sequence but not the 5'UTR sequence. In other words, it was found that by having the 5'UTR sequence of GAPDH and the 3'UTR sequence of GAPDH, a synergistic effect of improving translation efficiency can be obtained.
[0101] On the other hand, from the results of Figure 9, the expression level of the artificially synthesized mRNA having the LDHB 5'UTR sequence and the LDHB 3'UTR sequence was equivalent to the sum of the expression level of the artificially synthesized mRNA having the 5'UTR sequence but not the 3'UTR sequence and the expression level of the artificially synthesized mRNA having the 3'UTR sequence but not the 5'UTR sequence. In other words, the effect obtained by having the LDHB 5'UTR sequence and the LDHB 3'UTR sequence was only an additive effect.
[0102] In addition, the results in Figure 10 show that the expression level of the artificially synthesized mRNA having the UTR sequence of ACAT2 is lower in translation efficiency than that of the artificially synthesized mRNA having no UTR sequence. The results in Figures 8 to 10 show that the synergistic effect of improving translation efficiency obtained by having the 5'UTR sequence and the 3'UTR sequence is an effect characteristic of GAPDH.
[0103] (iv) Experiment 4 FIG. 11 is a diagram showing the prepared artificially synthesized mRNA. The artificially synthesized mRNAs shown in FIG. 11 are, from the top, an artificially synthesized mRNA having a 5'UTR sequence of GAPDH and a 3'UTR sequence of GAPDH (hereinafter also referred to as "wild type"), an artificially synthesized mRNA in which the most 5'-terminal part of the 3-part 5'UTR sequence is deleted (deletion mutant 1), an artificially synthesized mRNA in which the central part of the 3-part 5'UTR sequence is deleted (deletion mutant 2), and an artificially synthesized mRNA in which the most 3'-terminal part of the 3-part 5'UTR sequence is deleted (deletion mutant 3). A cap structure is added to the 5'-end of the artificially synthesized mRNA used in this experiment, and a 72-base polyA chain is added to the 3'-end. In addition, the ORF, which is the protein coding region of the artificially synthesized mRNA used in this experiment, has EGFP.
[0104] Fig. 12 shows the difference in expression level caused by the presence or absence of deletion of the 5'UTR sequence of GAPDH. The protein expression level was measured by introducing the artificially synthesized mRNA shown in Fig. 11 into HeLa cells. Fig. 12 shows the relative expression level when the wild-type expression level is set to 100.
[0105] FIG. 13 is a diagram showing the prepared artificially synthesized mRNA. The artificially synthesized mRNAs shown in FIG. 13 are, from the top, an artificially synthesized mRNA (wild type) having the 5'UTR sequence of GAPDH and the 3'UTR sequence of GAPDH, an artificially synthesized mRNA in which the most 5'-terminal part of the 3'UTR sequence divided into three parts is deleted (deletion mutant 4), an artificially synthesized mRNA in which the central part of the 3'UTR sequence divided into three parts is deleted (deletion mutant 5), and an artificially synthesized mRNA in which the most 3'-terminal part of the 3'UTR sequence divided into three parts is deleted (deletion mutant 6). A cap structure is added to the 5' end of the artificially synthesized mRNA used in this experiment, and a 72-base polyA chain is added to the 3' end. In addition, the ORF, which is the protein coding region of the artificially synthesized mRNA used in this experiment, has EGFP.
[0106] Fig. 14 shows the difference in expression level caused by the presence or absence of deletion of the 3'UTR sequence of GAPDH. Protein expression levels were measured by introducing the artificially synthesized mRNA shown in Fig. 13 into HeLa cells. In Fig. 14, the expression level is shown as a relative value when the expression level of the wild type is set to 100.
[0107] 12 and 14, it was found that the expression efficiency was reduced in all deletion mutants compared to the wild type, indicating that the presence of the entire regions of both the 5'UTR sequence of GAPDH and the 3'UTR sequence of GAPDH contributed to the improvement of translation efficiency.
[0108] (v) Experiment 5 FIG. 15 is a diagram showing the prepared artificially synthesized mRNA. In general, the 5'UTR sequence of GAPDH has complementarity with the 3'UTR sequence of GAPDH over the entire region. In this experiment, an artificially synthesized mRNA having a part of the 5'UTR sequence and a part of the 3'UTR sequence, which are regions with particularly high complementarity to each other, was used. Specifically, as the 5'UTR sequence, a CU-rich region (28 nucleotides) (hereinafter also referred to as "5'UTR 28nt"), which is the most 5'-terminal part of the 5'UTR sequence of GAPDH divided into three parts, was used. As the 3'UTR sequence of GAPDH, an AG-rich region (28 nucleotides) (hereinafter also referred to as "3'UTR 28nt"), which is the most 5'-terminal part of the 3'UTR sequence of GAPDH divided into three parts, was used.
[0109] Figure 16 shows the difference in expression level due to the presence or absence of 5'UTR 28nt and 3'UTR 28nt. Protein expression levels were measured by introducing artificially synthesized mRNA into HeLa cells. In Figure 16, the relative expression levels are shown when the wild-type expression level is set to 1.
[0110] From the results in Figure 16, it was found that the translation efficiency of the artificially synthesized mRNA having at least one of 5'UTR 28nt and 3'UTR 28nt was lower than that of the wild type. This result also shows that the presence of the entire region of both the 5'UTR sequence of GAPDH and the 3'UTR sequence of GAPDH contributes to the improvement of the translation efficiency.
[0111] (vi) Experiment 6 Figure 17 is a diagram showing the prepared artificial synthetic mRNA. In this experiment, an artificial synthetic mRNA having a 5'UTR sequence of GAPDH and a 3'UTR sequence having a predetermined complementarity to the 5'UTR sequence of GAPDH was used. Specifically, the artificial synthetic mRNAs shown in Figure 17 are, from the top, an artificial synthetic mRNA having a 3'UTR sequence having 94% complementarity to the 5'UTR sequence of GAPDH, an artificial synthetic mRNA having a 3'UTR sequence having 88% complementarity to the 5'UTR sequence of GAPDH, an artificial synthetic mRNA having a 3'UTR sequence having 75% complementarity to the 5'UTR sequence of GAPDH, an artificial synthetic mRNA having a 3'UTR sequence having 50% complementarity to the 5'UTR sequence of GAPDH, and an artificial synthetic mRNA having a 3'UTR sequence having 25% complementarity to the 5'UTR sequence of GAPDH. The artificially synthesized mRNA used in this experiment had a cap structure added to the 5' end and a 72-base polyA tail added to the 3' end. The ORF, which is the protein coding region of the artificially synthesized mRNA used in this experiment, contains EGFP.
[0112] Figure 18 shows the difference in expression level due to complementation. Protein expression levels were measured by introducing artificially synthesized mRNA into HeLa cells. In Figure 18, the expression level is shown as a relative value when the wild-type expression level is set to 1.
[0113] The results in Figure 18 show that artificial synthetic mRNA having a 3'UTR sequence that is 50% complementary to the GAPDH 5'UTR sequence and artificial synthetic mRNA having a 3'UTR sequence that is 75% complementary to the GAPDH 5'UTR sequence exhibit translation efficiency that is more than 2.5 times higher than that of the wild type.
[0114] Figure 19 shows the artificially synthesized mRNA that was prepared. In this experiment, an artificially synthesized mRNA was used that has the 5'UTR sequence of GAPDH and a 3'UTR sequence that is 100% complementary to the 5'UTR sequence of GAPDH. A cap structure was added to the 5' end of the artificially synthesized mRNA used in this experiment, and a 72-base polyA tail was added to the 3' end. In addition, the ORF, which is the protein coding region of the artificially synthesized mRNA used in this experiment, has EGFP.
[0115] Figure 20 shows the difference in expression level due to complementation. Protein expression levels were measured by introducing artificially synthesized mRNA into HeLa cells. Figure 20 shows the relative expression levels when the wild-type expression level is set to 100.
[0116] As shown in Figure 20, the artificially synthesized mRNA having a 3'UTR sequence with 100% complementarity to the 5'UTR sequence of GAPDH did not show protein expression. This result indicates that it is important to have a 3'UTR sequence with partial complementarity to the 5'UTR sequence of GAPDH.
[0117] (vii) Experiment 7 Figure 21 shows the artificially synthesized mRNA that was prepared. A cap structure was added to the 5' end of the artificially synthesized mRNA used in this experiment, and a 72-base polyA tail was added to the 3' end. In addition, this experiment was aimed at practical application, and the ORF of the tumor suppressor gene p53 was used as the protein coding region. A 5xFlag tag was added to the ORF.
[0118] Fig. 22 shows the difference in expression level when the tumor suppressor gene p53 is used. The protein expression level was measured by introducing artificially synthesized mRNA into U2OS cells. In Fig. 22, the expression level is shown as a relative value when the expression level of an artificially synthesized mRNA having a 3'UTR sequence with 75% complementarity to the 5'UTR sequence of GAPDH is set to 100.
[0119] The results in Figure 22 show that compared with artificial synthetic mRNA having the 3'UTR sequence of β-globin, which is the standard used artificial synthetic mRNA with high expression efficiency, the wild-type exhibits approximately 4-fold higher translation efficiency, and that artificial synthetic mRNA having a 3'UTR sequence with 75% complementarity to the 5'UTR sequence of GAPDH exhibits approximately 10-fold higher translation efficiency.
[0120] FIG. 23 is a diagram for explaining the estimated mechanism of the obtained effect. The artificial synthetic mRNA of this embodiment comprises a 5' untranslated region of GAPDH and a 3' untranslated region of GAPDH. Alternatively, the artificial synthetic mRNA of this embodiment comprises a 5' untranslated region and a 3' untranslated region having a complementarity of 40% or more and 80% or less with the 5' untranslated region. In other words, in the artificial synthetic mRNA of this embodiment, both 3' UTR sequences are partially complementary to the 5' UTR sequence of GAPDH. It is believed that such partial complementarity promotes the circularization of the mRNA, thereby efficiently recycling ribosomes, thereby improving translation efficiency.
[0121] (viii) Experiment 8 Figure 24 is a diagram showing the difference in expression level when the genome editing gene hCas9 is used. The vertical axis of the figure shows the expression level (expression (fold increase)). In this experiment, the following mRNA was used. The figure shows the relative value of the expression level when the expression level when there is no 5'UTR sequence and 3'UTR sequence is set to 1. Genome editing gene hCas9 (control) without 5´UTR and 3´UTR sequences ·Artificially synthesized mRNA containing the 5´UTR sequence of GAPDH An artificially synthesized mRNA that has the 5´UTR sequence of GAPDH and a 3´UTR sequence that is 75% complementary to the 5´UTR sequence of GAPDH. An artificially synthesized mRNA that has the 5´UTR sequence of GAPDH and a 3´UTR sequence that is 50% complementary to the 5´UTR sequence of GAPDH.
[0122] The results in Figure 24 show that, compared with the genome editing gene hCas9 which does not have a 5'UTR sequence or a 3'UTR sequence, the artificial synthetic mRNA having the 5'UTR sequence of GAPDH exhibits more than twice the translation efficiency, and the artificial synthetic mRNA having a 3'UTR sequence which is 75% complementary to the 5'UTR sequence of GAPDH and the artificial synthetic mRNA having a 3'UTR sequence which is 50% complementary to the 5'UTR sequence of GAPDH exhibit more than five times the translation efficiency.
[0123] Figure 25 is a diagram showing the difference in genome editing amount when the genome editing gene hCas9 is used. The vertical axis of the figure shows the genome editing amount (genome editing (fold increase)). In this experiment, the same mRNA as in Figure 24 was used. The figure shows the relative value of the genome editing amount when the genome editing amount of the genome editing gene hCas9 without the 5'UTR sequence and the 3'UTR sequence is set to 1.
[0124] The results in Figure 25 show that, compared with the genome editing gene hCas9 which does not have a 5'UTR sequence or a 3'UTR sequence, the artificial synthetic mRNA having the 5'UTR sequence of GAPDH showed more than twice the amount of genome editing, and the artificial synthetic mRNA having a 3'UTR sequence which is 75% complementary to the 5'UTR sequence of GAPDH and the artificial synthetic mRNA having a 3'UTR sequence which is 50% complementary to the 5'UTR sequence of GAPDH showed more than three times the amount of genome editing.
[0125] (ix) Experiment 9 26 is a diagram showing the difference in expression level when the 5'UTR of β-globin is used. The vertical axis of the diagram shows the expression level (expression (fold increase)). The following mRNAs were used in this experiment. The diagram shows the relative values of the expression level when the expression level of an artificially synthesized mRNA that does not have the 5'UTR sequence and the 3'UTR sequence is set to 1. -An artificially synthesized mRNA that has the 5´UTR sequence of β-globin and a 3´UTR sequence that is 100% complementary to the 5´UTR sequence of β-globin. -An artificially synthesized mRNA that has the 5´UTR sequence of β-globin and a 3´UTR sequence that is 92% complementary to the 5´UTR sequence of β-globin. -An artificially synthesized mRNA that has the 5´UTR sequence of β-globin and a 3´UTR sequence that is 88% complementary to the 5´UTR sequence of β-globin. -An artificially synthesized mRNA that has the 5´UTR sequence of β-globin and a 3´UTR sequence that is 74% complementary to the 5´UTR sequence of β-globin. -An artificially synthesized mRNA that has the 5´UTR sequence of β-globin and a 3´UTR sequence that is 50% complementary to the 5´UTR sequence of β-globin. -An artificially synthesized mRNA that has the 5´UTR sequence of β-globin and a 3´UTR sequence that is 24% complementary to the 5´UTR sequence of β-globin. -Artificially synthesized mRNA that has the 5´UTR sequence of β-globin but does not have the 3´UTR sequence Artificially synthesized mRNA that does not have the 5´UTR sequence or the 3´UTR sequence -Artificially synthesized mRNA containing the 5´UTR sequence of GAPDH and the 3´UTR sequence of GAPDH
[0126] The results in Figure 26 show that artificial synthetic mRNA having a 3'UTR sequence that is 74% complementary to the 5'UTR sequence of β-globin and artificial synthetic mRNA having a 3'UTR sequence that has a 3'UTR sequence that is 50% complementary to the 5'UTR sequence of β-globin show excellent translation efficiency.
[0127] (x) Experiment 10 27 is a diagram showing the difference in expression level when the 5'UTR of RPS8 is used. The vertical axis of the diagram shows the expression level (fold increase). The following mRNAs were used in this experiment. The diagram shows the relative expression level when the expression level of an artificially synthesized mRNA not having the 5'UTR sequence and the 3'UTR sequence is set to 1. An artificially synthesized mRNA having the 5´UTR sequence of RPS8 and a 3´UTR sequence that is 100% complementary to the 5´UTR sequence of RPS8. An artificially synthesized mRNA that has the 5´UTR sequence of RPS8 and a 3´UTR sequence that is 93% complementary to the 5´UTR sequence of RPS8. An artificially synthesized mRNA that has the 5´UTR sequence of RPS8 and a 3´UTR sequence that is 86% complementary to the 5´UTR sequence of RPS8. An artificially synthesized mRNA that has the 5´UTR sequence of RPS8 and a 3´UTR sequence that is 71% complementary to the 5´UTR sequence of RPS8. An artificially synthesized mRNA having the 5´UTR sequence of RPS8 and a 3´UTR sequence that is 50% complementary to the 5´UTR sequence of RPS8. An artificially synthesized mRNA having the 5´UTR sequence of RPS8 and a 3´UTR sequence that is 29% complementary to the 5´UTR sequence of RPS8. An artificially synthesized mRNA having the 5´UTR sequence of RPS8 and a 3´UTR sequence that is 14% complementary to the 5´UTR sequence of RPS8. -Artificially synthesized mRNA that has the 5´UTR sequence of RPS8 but does not have the 3´UTR sequence Artificially synthesized mRNA that does not have the 5´UTR sequence or the 3´UTR sequence -Artificially synthesized mRNA containing the 5´UTR sequence of GAPDH and the 3´UTR sequence of GAPDH
[0128] The results in Figure 27 show that artificial synthetic mRNA having a 3'UTR sequence that is 71% complementary to the 5'UTR sequence of RPS8 and artificial synthetic mRNA having a 3'UTR sequence that has a 3'UTR sequence that is 50% complementary to the 5'UTR sequence of RPS8 show excellent translation efficiency.
[0129] (x) Experiment 10 28 is a diagram showing the difference in expression level when the LDHB 5'UTR is used. The vertical axis of the diagram shows the expression level (expression (fold increase)). The following mRNAs were used in this experiment. The diagram shows the relative expression level when the expression level of an artificially synthesized mRNA having the LDHB 5'UTR sequence and no 3'UTR sequence is set to 1. An artificially synthesized mRNA having the 5´UTR sequence of LDHB and a 3´UTR sequence that is 100% complementary to the 5´UTR sequence of LDHB. -An artificially synthesized mRNA having the 5´UTR sequence of LDHB and a 3´UTR sequence that is 93% complementary to the 5´UTR sequence of LDHB. -An artificially synthesized mRNA having the 5´UTR sequence of LDHB and a 3´UTR sequence that is 87% complementary to the 5´UTR sequence of LDHB. -An artificially synthesized mRNA having the 5´UTR sequence of LDHB and a 3´UTR sequence that is 75% complementary to the 5´UTR sequence of LDHB. An artificially synthesized mRNA having the 5´UTR sequence of LDHB and a 3´UTR sequence that is 50% complementary to the 5´UTR sequence of LDHB. -An artificially synthesized mRNA having the 5´UTR sequence of LDHB and a 3´UTR sequence that is 25% complementary to the 5´UTR sequence of LDHB. -Artificially synthesized mRNA containing the 5´UTR sequence of LDHB but not the 3´UTR sequence
[0130] The results in Figure 28 show that artificial synthetic mRNA having a 3'UTR sequence that is 75% complementary to the LDHB 5'UTR sequence and artificial synthetic mRNA having a 3'UTR sequence that has a 3'UTR sequence that is 50% complementary to the LDHB 5'UTR sequence show excellent translation efficiency. [Industrial Applicability]
[0131] According to the present invention, the translation efficiency of the artificially synthesized mRNA introduced into the target cell is improved, and the target gene can be highly expressed. The applications of the present invention are expected to be, for example, mRNA medicines (treatment of various viral diseases, cancer immunotherapy, etc.), production of iPS cells, and differentiation induction of stem cells or progenitor cells.
[0132] The present invention is not limited to the above-mentioned embodiment and examples. Various modifications within the scope of the claims and within the scope that can be easily conceived by a person skilled in the art are also included in the present invention. The contents of papers, published patent publications, patent publications, etc. specified in this specification are all incorporated by reference.
Claims
1. the 5' untranslated region of an mRNA encoding a protein; a 3' untranslated region having a complementarity of 40% or more and 80% or less to the 5' untranslated region; An artificially synthesized mRNA comprising:
2. The artificial synthetic mRNA according to claim 1, The protein is an artificially synthesized mRNA selected from the group consisting of glyceraldehyde-3-phosphate dehydrogenase, β-globin, RPS8, and LDHB.
3. The artificial synthetic mRNA according to claim 1 or 2, The 3' untranslated region has a complementarity of 50% or more and 75% or less to the 5' untranslated region.
4. A method comprising the step of introducing the artificial synthetic mRNA according to any one of claims 1 to 3 into a cell (excluding a cell in a human body).
5. A cell into which the artificial synthetic mRNA according to any one of claims 1 to 3 has been introduced.
6. A method for producing an artificial synthetic mRNA, comprising the step of preparing an artificial synthetic mRNA comprising a 5' untranslated region of an mRNA encoding a protein and a 3' untranslated region having a complementarity of 40% or more and 80% or less with the 5' untranslated region.
Citation Information
Patent Citations
METHOD FOR MEASURING GAPDH mRNA
JP2012100593A
METHOD OF IMPROVING TRANSLATIONAL EFFICIENCY OF ARTIFICIAL SYNTHETIC mRNA
JP2015221026A
Artificial synthetic mRNA stabilizing method
JP2015226531A
METHOD FOR IMPROVING EXPRESSION OF ARTIFICIAL SYNTHETIC mRNA
JP2018074954A
Subcutaneous delivery of messenger RNA
WO2018089846A1
